Esperion Therapeutics Ne (ESPR) Share Value Rose While Emory University Cut Stake by $639,550; Third Avenue Management Raised Its World Fuel Services (INT) Position

February 24, 2018 - By Richard Conner

Emory University decreased its stake in Esperion Therapeutics Inc Ne (ESPR) by 27.35% based on its latest 2017Q3 regulatory filing with the SEC. Emory University sold 12,791 shares as the company’s stock rose 33.24% with the market. The institutional investor held 33,975 shares of the health care company at the end of 2017Q3, valued at $1.70M, down from 46,766 at the end of the previous reported quarter. Emory University who had been investing in Esperion Therapeutics Inc Ne for a number of months, seems to be less bullish one the $2.09 billion market cap company. The stock increased 1.23% or $0.96 during the last trading session, reaching $78.9. About 282,956 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 133.75% since February 24, 2017 and is uptrending. It has outperformed by 117.05% the S&P500.

Martin Whitman increased its stake in World Fuel Services Corp (INT) by 5.47% based on its latest 2017Q3 regulatory filing with the SEC. Third Avenue Management Llc bought 9,100 shares as the company’s stock declined 2.77% while stock markets rallied. The hedge fund run by Martin Whitman held 175,419 shares of the oil refining and marketing company at the end of 2017Q3, valued at $5.95M, up from 166,319 at the end of the previous reported quarter. Third Avenue Management Llc who had been investing in World Fuel Services Corp for a number of months, seems to be bullish on the $1.46B market cap company. The stock decreased 13.82% or $3.47 during the last trading session, reaching $21.64. About 2.02M shares traded or 291.09% up from the average. World Fuel Services Corporation (NYSE:INT) has declined 14.76% since February 24, 2017 and is downtrending. It has underperformed by 31.46% the S&P500.

Investors sentiment decreased to 0.87 in 2017 Q3. Its down 0.13, from 1 in 2017Q2. It worsened, as 26 investors sold INT shares while 78 reduced holdings. 26 funds opened positions while 64 raised stakes. 59.03 million shares or 1.86% less from 60.15 million shares in 2017Q2 were reported. Dimensional Fund Lp holds 2.95 million shares or 0.04% of its portfolio. Commonwealth Of Pennsylvania School Empls Retrmt, Pennsylvania-based fund reported 9,991 shares. Royal Savings Bank Of Canada accumulated 365,590 shares or 0.01% of the stock. Blackrock Inc holds 5.74 million shares. Moreover, Millennium Management Lc has 0% invested in World Fuel Services Corporation (NYSE:INT) for 28,220 shares. Cornerstone Cap Mgmt Holdg Ltd Limited Liability Company invested 0.09% of its portfolio in World Fuel Services Corporation (NYSE:INT). Bryn Mawr Trust Co holds 0.12% or 64,287 shares in its portfolio. 64,419 were reported by Metropolitan Life. Td Asset holds 6,023 shares. California State Teachers Retirement accumulated 129,910 shares. Secor Cap Advsrs Limited Partnership owns 138,406 shares for 0.45% of their portfolio. Motco owns 177 shares for 0% of their portfolio. Valley Natl Advisers Inc reported 1,050 shares. Ameritas Invest Prtnrs Incorporated, a Nebraska-based fund reported 20,615 shares. Alphaone Services Ltd Co reported 3,266 shares stake.

Third Avenue Management Llc, which manages about $2.22B US Long portfolio, decreased its stake in Valley National Bancorp (NYSE:VLY) by 93,300 shares to 189,675 shares, valued at $2.29 million in 2017Q3, according to the filing. It also reduced its holding in Alleghany Corp. (NYSE:Y) by 8,465 shares in the quarter, leaving it with 69,217 shares, and cut its stake in Standard Motor Products Inc. (NYSE:SMP).

Among 5 analysts covering World Fuel Services Corp (NYSE:INT), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. World Fuel Services Corp had 13 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Monday, February 22 by Bank of America. Stephens downgraded it to “Equal Weight” rating and $44 target in Friday, July 31 report. Bank of America downgraded the shares of INT in report on Friday, July 31 to “Underperform” rating. The stock has “Buy” rating by Stifel Nicolaus on Thursday, July 27. The firm has “Hold” rating given on Friday, February 9 by Seaport Global. The rating was downgraded by Bank of America to “Sell” on Tuesday, September 26. Bank of America maintained the stock with “Underperform” rating in Friday, September 11 report. The stock of World Fuel Services Corporation (NYSE:INT) earned “Neutral” rating by Credit Suisse on Friday, April 29. The stock of World Fuel Services Corporation (NYSE:INT) has “Buy” rating given on Friday, February 23 by Stifel Nicolaus. The stock of World Fuel Services Corporation (NYSE:INT) has “Buy” rating given on Friday, November 4 by Stifel Nicolaus.

Emory University, which manages about $126.35M US Long portfolio, upped its stake in Ra Pharmaceuticals Inc by 48,940 shares to 112,084 shares, valued at $1.64 million in 2017Q3, according to the filing. It also increased its holding in Myovant Sciences Ltd by 28,075 shares in the quarter, for a total of 157,303 shares, and has risen its stake in Biocryst Pharmaceuticals (NASDAQ:BCRX).

Among 18 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 0 Sell and 8 Hold. Therefore 56% are positive. Esperion Therapeutics had 56 analyst reports since July 28, 2015 according to SRatingsIntel. WallachBeth Capital initiated Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Monday, October 26 with “Buy” rating. Citigroup downgraded the shares of ESPR in report on Monday, January 22 to “Hold” rating. As per Wednesday, August 9, the company rating was upgraded by Jefferies. The rating was maintained by Needham with “Buy” on Wednesday, February 21. The rating was downgraded by Credit Suisse to “Underperform” on Wednesday, June 29. The firm earned “Neutral” rating on Monday, November 14 by Citigroup. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Buy” rating by Lake Street on Monday, October 26. The company was downgraded on Friday, September 4 by Zacks. The firm earned “Buy” rating on Thursday, February 25 by Stifel Nicolaus. JMP Securities maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $67 target.

Investors sentiment increased to 1.67 in Q3 2017. Its up 0.45, from 1.22 in 2017Q2. It increased, as 11 investors sold ESPR shares while 34 reduced holdings. 30 funds opened positions while 45 raised stakes. 22.73 million shares or 17.55% more from 19.33 million shares in 2017Q2 were reported. Gsa Cap Prns Llp stated it has 0.03% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). New York-based Perceptive Advsrs Limited Com has invested 0.02% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Benjamin F Edwards And Co has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Schwab Charles Investment Mgmt holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 91,843 shares. Natl Bank Of America De holds 34,781 shares. 15,640 are held by Proshare Advsrs Lc. Pentwater Cap Ltd Partnership invested 0.96% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). California Public Employees Retirement Systems holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 48,158 shares. Parallax Volatility Advisers Lp reported 10,469 shares stake. Wasatch Advisors reported 713,404 shares. Barclays Public Ltd Com reported 1,539 shares or 0% of all its holdings. The Massachusetts-based Amundi Pioneer Asset Management Inc has invested 0.03% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). 1,310 were accumulated by Ameritas Invest Partners. Hall Laurie J Trustee accumulated 280 shares. The Illinois-based Guggenheim Cap Llc has invested 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: